FOLFOXIRI + Bevacizumab

DRUG4 trials

Sponsors

Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Sun Yat-sen University, Yanqiao Zhang, Sixth Affiliated Hospital, Sun Yat-sen University

Conditions

Colorectal CancerMetastatic Colorectal CancerPhase 2 Study

Phase 2

FOLFOXIRI With or Without Bevacizumab as First-line Treatment for Unresectable Liver-only Metastatic Colorectal Cancer Patients With RAS Mutation-type

CompletedNCT02350530

Sun Yat-sen UniversityMetastatic Colorectal Cancer

Start: 2015-01-01End: 2020-01-01Target: 138Updated: 2026-05-22

A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation

Not yet recruitingNCT07229846

Yanqiao ZhangColorectal Cancer

Start: 2026-02-28End: 2028-02-29Target: 30Updated: 2026-01-08

mFOLFOXIRI Plus Bevacizumab for Organ Preservation in Locally Advanced Rectal Cancer

Not yet recruitingNCT07817888

Sixth Affiliated Hospital, Sun Yat-sen UniversityPhase 2 Study

Start: 2026-09-30End: 2031-09-30Target: 119Updated: 2026-09-14

Phase 3

Study of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) + Bevacizumab Versus 5-Fluorouracil/Leucovorin/Oxaliplatin/Irinotecan (FOLFOXIRI) + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells

CompletedNCT01640405

Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)Metastatic Colorectal Cancer

Start: 2012-07-31End: 2018-11-30Updated: 2019-04-11

Related Papers

Associations of blood RNA biomarkers and circulating tumour cells in patients with previously untreated metastatic colorectal cancer.

2025-04-21

Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNÚ-1 and Phase II VISNÚ-2 Randomized Trials.

2023-02-214 citations

Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected.

2020-03-0628 citations

Safety analysis of a phase III randomized trial comparing FOLFOX + Bevacizumab vs FOLFOXIRI + Bevacizumab as 1st line treatment in patients with metastatic colorectal cancer (mCRC) with ≥3 circulating tumor cells (CTCs) (VISNÚ-1 TTD TRIAL).

Journal of Clinical Oncology2018-05-203 citations

FOLFOXIRI with or without bevacizumab as first-line treatment for unresectable liver-only metastatic colorectal cancer patients with RAS mutation-type.

Journal of Clinical Oncology2015-05-201 citations